Genzyme, Isis Start Pivotal Trial for High Cholesterol
Luke Timmerman8/6/08
Cambridge, MA-based Genzyme (NASDAQ: GENZ) and its partner, Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: ISIS), said today they have started a pivotal clinical trial for patients with a genetic disorder that causes exceptionally high levels of cholesterol. The study will enroll 100 patients in the U.S. and Canada, to take 200 milligrams of the experimental drug mipomersen or a placebo each week for about six months. Data from the trial, the first of four new studies the companies plan to initiate by year’s end, will be available in 2010.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
